New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold
Trial Timeline
Nov 30, 2017 → Apr 16, 2018
NCT ID
NCT03339726About New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Common Cold. The current trial status is terminated. This product is registered under clinical trial identifier NCT03339726. Target conditions include Common Cold.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03339726 | Phase 2 | Terminated |
Competing Products
20 competing products in Common Cold